Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2392558 | 0.78 | CA4 (0.36) | — | |
| SCHEMBL1284011 | 0.78 | HMGCR (0.33) | HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL14914212 | 0.76 | HMGCR (0.40) | CA2HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL25007292 | 0.72 | FAAH (0.42) | CA2FAAH | |
| SCHEMBL5070082 | 0.72 | FAAH (0.37) | FAAH | |
| T-Butylacetic Acid SCHEMBL6567111 | 0.72 | CA4 (0.42) | CA2 | |
| SCHEMBL28462712 | 0.70 | FAAH (0.36) | FAAH | |
| T-Butylacetic Acid SCHEMBL11218671 | 0.69 | — | — | |
| T-Butylacetic Acid SCHEMBL6500330 | 0.69 | — | — | |
| SCHEMBL3697055 | 0.69 | HMGCR (0.41) | CA2HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076350-B2 | 3H-(4's)-1'-azaspiro[benzofuran-2,4']-tricyclo[3.3.1.13,7]decane; for therapy of memory disorder, cognitive disorder, neurodegeneration, and neurodevelopmental disorder; attention deficit disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment | ABBOTT LABORATORIES (US) | 2011-12-13 | — | — | US | disclosed |
| US-20080153860-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153860-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | NR3C2, REN, GNE | CA2 2667/4885HMGCR 191/4885CHRM1 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.